NASDAQ:AMIX - US05330T2050 - Common Stock
The current stock price of AMIX is 1.18 USD. In the past month the price decreased by -9.92%. In the past year, price decreased by -92.61%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 26.98 | 230.05B | ||
BSX | BOSTON SCIENTIFIC CORP | 38 | 159.33B | ||
ISRG | INTUITIVE SURGICAL INC | 54.8 | 158.15B | ||
SYK | STRYKER CORP | 30.24 | 148.55B | ||
MDT | MEDTRONIC PLC | 16.68 | 118.33B | ||
BDX | BECTON DICKINSON AND CO | 13.29 | 54.35B | ||
IDXX | IDEXX LABORATORIES INC | 52.79 | 50.72B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.6 | 47.68B | ||
RMD | RESMED INC | 28.19 | 39.42B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.53 | 33.05B | ||
DXCM | DEXCOM INC | 46.42 | 30.95B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.16 | 26.14B |
Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. The company is headquartered in The Woodlands, Texas and currently employs 8 full-time employees. The company went IPO on 2024-01-29. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. The company is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The firm is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.
AUTONOMIX MEDICAL INC
21 Waterway Ave, Suite 300
The Woodlands TEXAS US
Employees: 10
Phone: 18322777816
The current stock price of AMIX is 1.18 USD. The price decreased by -4.84% in the last trading session.
The exchange symbol of AUTONOMIX MEDICAL INC is AMIX and it is listed on the Nasdaq exchange.
AMIX stock is listed on the Nasdaq exchange.
8 analysts have analysed AMIX and the average price target is 6.73 USD. This implies a price increase of 470.51% is expected in the next year compared to the current price of 1.18. Check the AUTONOMIX MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AUTONOMIX MEDICAL INC (AMIX) has a market capitalization of 6.99M USD. This makes AMIX a Nano Cap stock.
AUTONOMIX MEDICAL INC (AMIX) currently has 10 employees.
AUTONOMIX MEDICAL INC (AMIX) has a resistance level at 1.25. Check the full technical report for a detailed analysis of AMIX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AMIX does not pay a dividend.
AUTONOMIX MEDICAL INC (AMIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.81).
The outstanding short interest for AUTONOMIX MEDICAL INC (AMIX) is 6.08% of its float. Check the ownership tab for more information on the AMIX short interest.
ChartMill assigns a fundamental rating of 2 / 10 to AMIX. AMIX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months AMIX reported a non-GAAP Earnings per Share(EPS) of -6.81. The EPS increased by 48.05% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -133.9% | ||
ROE | -171.32% | ||
Debt/Equity | 0 |
8 analysts have analysed AMIX and the average price target is 6.73 USD. This implies a price increase of 470.51% is expected in the next year compared to the current price of 1.18.